Melanoma Treatment Market: By Therapy (Radiation Therapy, Chemotherapy, Targeted Therapy, Others), By Type (Mucosal Melanoma, Ocular Melanoma, Cutaneous Melanoma) Regional Analysis and Forecast – 2026

  • OI-19
  • |
  • Published date: May, 2019
  • |
  • Oncology/Hematology
  • |
  • Pages


Melanoma is a type of cancer that starts in skin cells that give skin its color. Melanoma has the potential to spread through the dermis to nearby tissues and other parts of the body. Melanoma can also form in the genitalia, mouth, nose, eyes, or rarely, in the internal organs. The deeper a melanoma grows into the dermis, the higher the risk of spreading through lymph vessels or blood vessels. According to the World Health Organization, a 10% ozone depletion is likely to result in an additional 300,000 non-melanoma and 4,500 melanoma cases. Approximately, 287,723 people are expected to develop melanoma by the end of 2018, with Europe and North America representing over 50.1% and 24.8% of the new cases respectively. Such high proportions of incident cases highlight an increased need for melanoma drugs in these regions over the forecast period.

Market Overview

The global Melanoma Treatment market was valued at $ XX Mn in 2018 and is forecast to grow at a strong XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The market is driven by due to robust medical research, high prevalence and changing the environmental landscape. However, the lack of comparative trials between new technologies is restraining market growth. Moreover, the development of next-generation therapies is providing ample opportunities for the market.

Melanoma Treatment depending on the type, Ocular Melanoma segment is expected to account for the largest share of the Melanoma Treatment market. Ocular melanoma is the most common cancer of the eye, with approximately 2,000 cases diagnosed annually.

Key Developments

  • On Feb 15, 2019: Merck has received FDA approval for pembrolizumab for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection

  • On May 8, 2019: IDEAYA has received Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for the development of IDE196 as a treatment for metastatic uveal melanoma


The global Melanoma Treatment in the Healthcare market is segmented on the basis of therapy, type, and region.

Based on the Therapy: Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, and Pharmacological Treatment.

Based on the Type: Mucosal Melanoma and Ocular Melanoma.

Based on the region: North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market owing to the rising incidence of melanoma and other skin cancers in the region. According to the CDC, over 87,100 people were affected by melanoma in 2017. As per the American Cancer Society, this number is expected to go up to 93,450 cases in 2021. These statistics highlight the need for drugs that help in the management of melanoma over the coming years.

The report covers in-depth analysis of Global Melanoma Treatment in the Healthcare Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by Type (Mucosal Melanoma, Ocular Melanoma, and Cutaneous Melanoma). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.

The report includes in-depth company profiles of key players in Global Melanoma Treatment in the Healthcare Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.

The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.


  • Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Melanoma Treatment in Healthcare Market.

  • Provides a comparative analysis of key marketed products and pipeline market products.

  • Provides key information on players involved in the Global Melanoma Treatment in the Healthcare Market.

  • Provides a complete overview of market segments and the regional outlook of Global Melanoma Treatment in the Healthcare Market.

  • Provides in-depth coverage of key news related to global Melanoma Treatment in Healthcare Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates




Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:

  • Data Collation (Primary & Secondary)

  • In-house Estimation (Based on proprietary databases and Models)

  • Market Triangulation

  • Forecasting

  • Market-related information is assembled from both primary and secondary sources. 

  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 

  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.

  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 



Choose Licence Type

Credit card Logo
Inquiry Before Buying

Related Reports

Contact Us

Email Us at: | Reach Us at: +91 966 6620 365 | +1 857 444 9369 (US)  tick-under  tick-under